⌘K
t
On 28 April 2025, Beximco Pharmaceuticals Limited requested an extension from the Bangladesh Securities and Exchange Commission, the Dhaka Stock Exchange, and the Chittagong Stock Exchange to submit and publish its Q3 Financial Statements. A Board of Directors meeting is required to approve the results, which is not currently possible. This is due to the Bangladesh Securities and Exchange Commission's proposed appointment of nine independent non-executive directors to the Company's Board remaining outstanding in the High Court of Bangladesh, as previously announced on 21 March 2025.
| Date | 28 Apr 2025 |
| Time | 07:00:08 |
| Category | Miscellaneous |
| ID | 3987G |
28 April 2025
BEXIMCO PHARMACEUTICALS LIMITED
Request of Extension to Publish Q3 Financial Results
Beximco Pharmaceuticals Limited ("the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces that the Company has written to the Bangladesh Securities and Exchange Commission (BSEC), the Dhaka Stock Exchange and the Chittagong Stock Exchange to request an extension to submit and publish the Q3 Financial Statements.
In order to approve the Q3 Financial Results for the Company, a meeting of the Board of Directors is required. This is not possible currently because, in line with the Company's previous announcement, dated 21 March 2025, BSEC's proposed appointment of an additional nine independent non-executive directors to the Company's Board of Directors remains outstanding in the High Court of Bangladesh.
Further announcements will be made as appropriate.
For further information please visit www.beximcopharma.com or enquire to:
|
Beximco Pharma |
|
Mohammad Ali Nawaz, Chief Financial Officer Tel: +880 2 58611001, Ext. 20030
Mohammad Asad Ullah, FCS Executive Director & Company Secretary Tel: +880 2 41060531, Ext. 10140
|
|
SPARK Advisory Partners Limited (Nominated Adviser) Mark Brady / Andrew Emmott Tel: +44 (0)20 3368 3551 / 3555
|
|
SP Angel Corporate Finance LLP (Broker) Matthew Johnson Tel: +44 (0) 20 3470 0470
|
|
FTI Consulting Simon Conway / Sam Purewal Tel: +44 (0)20 3727 1000
|
Notes to Editors
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.